Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT05031494 : A Multi-center, Open-label Phase II Study to Evaluate the Safety and Efficacy of YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Patients With Unresectable/Metastatic Melanoma and Pancreatic Ductal Adenocarcinoma (PDAC)

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy,Treatment | Skin,Stomach and upper gastrointestinal tractMelanoma (Skin),Pancreas

Trial Overview Read MoreRead more

This phase II study is evaluating how safe and effective a new cancer drug (YH003) is in combination with targeted therapy (toripalimab), and how these drugs combine with chemotherapy, in people with metastatic melanoma and pancreas cancer.
 

This trial is treating patients with melanoma and pancreas cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has not spread to other parts of the body.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Multi-center, Open-label Phase II Study to Evaluate the Safety and Efficacy of YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Patients With Unresectable/Metastatic Melanoma and Pancreatic Ductal Adenocarcinoma (PDAC)

Commercial Sponsor

Eucure (Beijing) Biopharma Co., Ltd

Summary

This study has three experimental cohorts. Cohort 1 will enrol participants with unresectable/metastatic melanoma, who will receive YH003 in combination with toripalimab. YH003 will be dosed at RP2D every 3 weeks and toripalimab will be administered at a dose of 240mg every 3 weeks. Cohort 2 will enrol participants with unresectable/metastatic pancreatic ductal adenocarcinoma as 2nd line treatment, who will receive YH003 with toripalimab. YH003 will be dosed at RP2D every 3 weeks and toripalimab will be administered at a dose of 240mg every 3 weeks. Cohort 3 will enrol people with unresectable/metastatic pancreatic ductal adenocarcinoma as 1st line treatment, who will receive YH003 with toripalimab plus standard chemotherapy. YH003 will be dosed at RP2D every 3 weeks, toripalimab will be administered at a dose of 2540 mg every 3 weeks, Nab-paclitaxel will be administered each 21-day cycle and gemcitabine will be administered each 21-day cycle.

Recruiting Hospitals Read MoreRead more

Epworth Hospital
Richmond
Ms Jenni Flynn
jenni.flynn@epworth.org.au
03 9936 8206

Epworth Freemasons, Jreissati Family Pancreatic Centre
East Melbourne
A/Prof Sumitra Ananda
EHJreissatiCentre@epworth.org.au
03 9426 8880

Epworth Richmond, Jreissati Family Pancreatic Centre
Richmond
A/Prof Sumitra Ananda
EHJreissatiCentre@epworth.org.au
03 9426 8880

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next